Clinical trials: Stage III Prostate Cancer AJCC v7
Depression, Cancer
Mindfulness-based Intervention for Depressive Symptoms Sent Via Text (MINDSET)
The purpose of this study is to develop and test a new intervention to reduce depressive symptoms in post-treatment cancer participants.
- Conditions
- Depression, Cancer, Stage III Breast Cancer, Stage II Breast Cancer
- Trial name
- NCT06811454
- Testing
- MINDSET, Enhanced Usual Care (EUC)
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- Case Comprehensive Cancer Center
Prostate Cancer
Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Prostate Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known whether radiation therapy to the prostate and pelvis is more effective than radiation therapy to the prostate alone in treating…
- Trial name
- NCT00003607
- Testing
- radiation therapy
- Where
- 23 sites in France
- Volunteers
- 450 people
- Sponsor
- UNICANCER
Prostate Cancer
Androgen Deprivation Therapy in Treating Patients With Prostate Cancer
RATIONALE: Androgens can cause the growth of prostate cancer cells. Androgen deprivation therapy may stop the adrenal glands from making androgens.
- Trial name
- NCT00110162
- Testing
- antiandrogen therapy, releasing hormone agonist therapy, orchiectomy
- Where
- 20 sites in Australia, New Zealand
- Volunteers
- 2,000 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Prostate Cancer
Study of Blood and Tissue Samples From Patients Receiving Androgen Deprivation for Newly Diagnosed Prostate Cancer
RATIONALE: Studying samples of blood and tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00967954
- Testing
- antiandrogen therapy, releasing hormone agonist therapy, DNA analysis
- Where
- United Kingdom
- Volunteers
- 120 people
- Sponsor
- Cancer Research UK
Prostate Cancer, Sexual Dysfunction
High-Intensity Focused Ultrasound Focal Ablation in Treating Patients With Progressive Prostate Cancer
RATIONALE: High-intensity focused ultrasound focal ablation uses high-energy sound waves to kill tumor cells. PURPOSE: This phase II trial is studying the side effects of high-intensity focused ultrasound focal ablation and to…
- Trial name
- NCT00988130
- Testing
- laboratory biomarker analysis, questionnaire administration, assessment of therapy complications
- Where
- United Kingdom
- Volunteers
- 26 people
- Sponsor
- University College London Hospitals
Gastrointestinal Complications, Prostate Cancer
RADICALS - Radiotherapy and Androgen Deprivation In Combination After Local Surgery
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Androgens can cause the growth of prostate cancer cells.
- Conditions
- Gastrointestinal Complications, Prostate Cancer, Sexual Dysfunction, Urinary Complications
- Trial name
- NCT00541047
- Testing
- bicalutamide, goserelin acetate, leuprolide acetate
- Where
- 58 sites in Canada, United Kingdom
- Volunteers
- 4,236 people
- Sponsor
- University College, London
Prostate Cancer
Implant Radiation Therapy Using Radioactive Iodine in Treating Patients With Localized Prostate Cancer
RATIONALE: Implant radiation therapy delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue.
- Trial name
- J-POPS (NCT00534196)
- Testing
- Permanent iodine-125 (Brachytherapy)
- Where
- 31 sites in Japan
- Volunteers
- 6,927 people
- Sponsor
- Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Nonmalignant Neoplasm, Prostate Cancer
Lycopene in Treating Patients With Prostate Cancer or Benign Prostatic Hyperplasia
RATIONALE: Chemoprevention is the use of certain substances to keep cancer from forming, growing, or coming back. Eating a diet high in lycopene, a substance found in tomatoes and tomato products, may keep cancer from forming or…
- Trial name
- NCT00416390
- Testing
- lycopene, laboratory biomarker analysis, biopsy
- Volunteers
- 120 people
- Sponsor
- University of Illinois Chicago
Prostate Cancer
Computed Tomography (CT) Scans Using CT-On-Rails™ to Pinpoint the Location of the Tumor in Treating Patients With Prostate Cancer
RATIONALE: New imaging procedures such as CT-on-rails™ may improve the ability to pinpoint the location of the tumor and decrease radiation therapy damage to healthy tissue.
- Trial name
- NCT00084526
- Testing
- computed tomography, ultrasound imaging
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Fox Chase Cancer Center
Prostate Cancer
Selenium in Treating Patients With Prostate Cancer
RATIONALE: Selenium may prevent or slow the growth of prostate cancer. PURPOSE: This randomized phase II trial is studying how well selenium works in treating patients with prostate cancer.
- Trial name
- NCT00752739
- Testing
- selenium
- Where
- United States
- Volunteers
- 220 people
- Sponsor
- University of Arizona
Prostate Cancer
Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Prostate Cancer
RATIONALE: Radiation therapy uses high-energy x-rays and other types of radiation to kill tumor cells. Giving radiation therapy in different ways may kill more tumor cells.
- Trial name
- NCT00258466
- Testing
- radiation therapy
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Osteoporosis, Prostate Cancer
Effect of Androgen Suppression on Bone Loss in Patients With or Without Bone Metastases Secondary to Prostate Cancer
RATIONALE: Assessing the effect of androgen suppression on bone loss in prostate cancer patients may improve the ability to plan treatment, may decrease the risk of fractures and bony pain, and may help patients live more…
- Trial name
- NCT00003903
- Testing
- management of therapy complications
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- University of Rochester
Prostate Cancer
Bicalutamide Compared With Observation Followed by Bicalutamide Plus Either Goserelin or Orchiectomy in Treating Patients With Prostate Cancer
RATIONALE: Testosterone can stimulate the growth of cancer cells. Bicalutamide and goserelin may fight prostate cancer by reducing the production of testosterone.
- Trial name
- NCT00014586
- Testing
- bicalutamide, goserelin acetate, orchiectomy
- Where
- Germany
- Volunteers
- 110 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Prostate Cancer
Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy
The overall aim of this trial, which is called STAMPEDE, is to assess novel approaches for the treatment of men with prostate cancer who are starting long-term ADT for the first time, termed hormone-naïve prostate cancer.
- Trial name
- STAMPEDE (NCT00268476)
- Testing
- Celecoxib, Docetaxel, Prednisolone
- Where
- 120 sites in Switzerland, United Kingdom
- Volunteers
- 11,992 people
- Sponsor
- Medical Research Council
Prostate Cancer
Positron Emission Tomography in Prostate Cancer
RATIONALE: Diagnostic procedures, such as positron emission tomography using carbon-11 acetate, may help find metastases from prostate cancer and may help predict whether prostate cancer will come back after treatment.
- Trial name
- NCT00121212
- Testing
- carbon-11 acetate PET scan
- Where
- United States
- Volunteers
- 179 people
- Sponsor
- Washington University School of Medicine
Prostate Cancer
Radiation Therapy Compared With No Further Treatment Following Surgery in Treating Patients With Prostate Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells and may be an effective treatment for prostate cancer.
- Trial name
- NCT00002511
- Testing
- low-LET photon therapy
- Where
- Belgium
- Volunteers
- 1,005 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Sedentary Lifestyle, Stage III Prostate Cancer AJCC v7
Fatigue Interventions in Cancer (Exercise Intervention)
This randomized pilot phase II trial studies how well exercise intervention with or without internet-based cognitive behavior therapy works in reducing fatigue in participants with prostate cancer that has spread to other places…
- Conditions
- Sedentary Lifestyle, Stage III Prostate Cancer AJCC v7, Stage IV Prostate Cancer AJCC v7
- Trial name
- NCT03421782
- Testing
- Cognitive Behavior Therapy, Exercise Intervention
- Where
- United States
- Volunteers
- 126 people
- Sponsor
- University of Utah
Prostate Cancer
Cyproterone Acetate in Treating Patients With Newly Diagnosed Stage III or Stage IV Prostate Cancer
RATIONALE: Androgens can cause the growth of prostate cancer cells. Hormone therapy, such as cyproterone acetate may stop the adrenal glands from making androgens. Sometimes the tumor may not need treatment until it progresses.
- Trial name
- NCT00363285
- Testing
- gonadotrophin releasing hormone, cyproterone acetate, quality-of-life assessment
- Where
- 2 sites in United Kingdom
- Volunteers
- 900 people
- Sponsor
- St. Bartholomew's Hospital
Breast Cancer, Lung Cancer
T-Cell Response in Patients Receiving Trastuzumab and/or Chemotherapy for HER2-Positive Solid Tumors
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors predict how well patients will respond to treatment. It may also help the study of cancer in the future.
- Conditions
- Breast Cancer, Lung Cancer, Ovarian Cancer, Prostate Cancer
- Trial name
- NCT00433407
- Testing
- trastuzumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Prostate Adenocarcinoma, Stage IIB Prostate Cancer AJCC v7
68Ga-PSMA-11 PET/CT in Imaging Patients With Intermediate or High Risk Prostate Cancer Before Surgery
This clinical trial studies how well 68Ga-PSMA-11 positron emission tomography (PET)/computed tomography (CT) works in imaging patients with intermediate or high risk prostate cancer before surgery.
- Conditions
- Prostate Adenocarcinoma, Stage IIB Prostate Cancer AJCC v7, Stage III Prostate Cancer AJCC v7, Stage IV Prostate Cancer AJCC v7
- Trial name
- NCT03368547
- Testing
- Computed Tomography, Gallium Ga 68 Gozetotide, Positron Emission Tomography
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- Jonsson Comprehensive Cancer Center